Clinical Trial

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-16.
Trial Details
NCT Number NCT06375239
Lead Sponsor Ray Therapeutics, Inc.
Collaborators: The Vision Research and Assessment Institute (VRAI)
Conditions Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
Enrollment 120 participants
Start Date 2024-04-05
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-08